Innovative Drug Development Programs Designed for Rapid Success
Furiex applies its expertise to design innovative drug development programs that meet critical endpoints, shorten timelines and maintain quality. The Furiex model conducts drug development using parallel processing resulting in fewer decision gates and removal of decision points. This fast and focused model can be applied to any therapeutic area and indication.
We use our drug development experience to predict possible outcomes of a study and take risks based on those predictions. By a priori assuming success at each critical decision point – as opposed to waiting for results to demonstrate success in order to make a decision – we can reduce timelines. Risks are mitigated by our disciplined approach and thorough contingency planning for potential issues that may arise. As a result, we accelerate the development process by bridging steps across the developmental program as well as between studies.
In addition, we focus our efforts on the essential studies necessary for regulatory approval and do not include extraneous studies primarily used for academic interest.
Proven Success
Our success is illustrated by the alogliptin and dapoxetine development programs. We advanced alogliptin, now a marketed product called Nesina®, from investigational new drug (IND) to new drug application (NDA) in 39 months. The proof of concept for dapoxetine, now a marketed product called Priligy®, was completed by us in one year. We apply this driven success to all of our partnered programs.
